Cancer biotech launches on NASDAQ

Israel’s UroGen has three treatments for the treatment of cancers of the urinary system (bladder and kidneys). It has just raised $58.2 million on NASDAQ. UroGen’s MitoGel treatment for Upper Tract Urothelial Carcinoma has received Orphan status from the US FDA.

http://www.globes.co.il/en/article-urogen-pharma-raises-582m-in-nasdaq-ipo-1001187475

https://www.youtube.com/embed/6aBvLhlUxh0?rel=0

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *